Levomilnacipran extended-release: A review of its use in adult patients with major depressive disorder

CNS Drugs

Volumn 28, Issue 11, 2014, Pages 1071-1082

  Scott, Lesley J ^a  

^a Springer Private Bag 65901 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; CARBAMAZEPINE; MILNACIPRAN; CYCLOPROPANE DERIVATIVE; DELAYED RELEASE FORMULATION; SEROTONIN UPTAKE INHIBITOR;

ADULT; ADULT DISEASE; ANGINA PECTORIS; AREA UNDER THE CURVE; CONTUSION; CONVULSION; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; ENANTIOMER; ERECTILE DYSFUNCTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; IC50; INHIBITION CONSTANT; ISCHEMIC HEART DISEASE; KIDNEY CLEARANCE; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SUICIDAL IDEATION; SUPRAVENTRICULAR TACHYCARDIA; VOLUME OF DISTRIBUTION; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; DRUG USE; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DRUG UTILIZATION REVIEW; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919924114     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0203-1     Document Type: Review

References (41)

1. Shim RS, Baltrus P, Ye J, et al. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008. J Am Board Fam Med. 2011;24(1):33-8.
2. Lepine J-P, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):3-7.
3. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35(1):1-14.
4. Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease study 2010. PLoS One. 2013;8(7):e69637.
5. Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-84.
6. Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011;34(1):1-9.
7. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease study 2010. PLoS Med. 2013;10(11):e1001547.
8. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder, 3rd edn. 2010. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485. Accessed 29 Jul 2014.
9. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.
10. Nutt DJ, Davidson JRT, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(Suppl E1):e08.
11. Forest Pharamceuticals Inc. Fetzima™ (levomilnacipran) extended-release capsules, for oral use: US prescribing information. 2013. http://www.frx.com/pi/fetzima-pi.pdf. Accessed 18 Jul 2014.
12. Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-47.
13. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55-68.
14. O'Connor J, Chen L, Gommoll C, et al. Levomilnacipran inhibits both norepinephrine and serotonin reuptake across the clinical dose range [abstract no. W191]. Neuropsychopharmacology. 2013;38(Suppl):S563-4.
15. Chen L, Chen C, Carrothers TJ et al. Evaluation of effects of sequential multiple-dose regimens of levomilnacipran ER on cardiac repolarization in healthy subjects [poster]. Presented at the American Society for Clinical Pharmacology and Therapeutics Meeting; March 18-22 2014, Atlanta.
16. Carrothers TJ, Khariton T, Chen C, et al. Population pharmacokinetic model for levomilnacipran in healthy subjects and patients with major depressive disorder [abstract no. T-008]. J Pharmacokinet Pharmacodyn. 2013;40(Suppl):S61-3.
17. Chen L, Periclou A, Ghahramani P et al. Pharmacokinetic characteristics of levomilnacipran sustained released capsule following single- and multiple-dose administration [poster]. Presented at the 166th Annual American Psychiatric Association Meeting; May 18-22 2013, San Francisco.
18. Chen L, Boinpally R, Gad N et al. Drug-drug interactions of levomilnacipran sustained release capsule with ketoconazole, carbamazepine, or alprazolam in healthy subjects [poster]. Presented at the 166th Annual American Psychiatric Association Meeting; May 18-22 2013, San Francisco.
19. Chen L, Carrothers TJ, Periclou A et al. A single-dose pharmacokinetic study of levomilnacipran SR in subjects with normal or impaired renal function [poster]. Presented at the 53rd Annual New Clinical Drug Evaluation Unit Meeting; May 28-31 2013, Hollywood.
20. Chen L, Boinpally R, Greenberg WM, et al. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. Clin Drug Investig. 2014;34(5):351-9.
21. Asnis GM, Bose A, Gommoll CP. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(3):242-8.
22. Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39(1):40-9.
23. Sambunaris A, Bose A, Gommoll CP, et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2013;29(10):47-56.
24. Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess. 2014;3:10-9.
25. Montgomery SA, Mansuy L, Ruth A, et al. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo- controlled, proof-of-concept study. J Clin Psychiatry. 2013;74(4):363-9.
26. Montgomery SA, Mansuy L, Ruth AC, et al. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2014;29(1):26-35.
27. Gommoll C, Greenberg WM, Chen C, et al. Post hoc analyses of levomilnacipran SR 40, 80, and 120 mg on functional outcomes in major depressive disorder [abstract no. P.2.b.018]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S329.
28. Montgomery S, Gommoll C, Chen C. Levomilnacipran SR efficacy in major depressive disorder (MDD) across patient subgroups: pooled analysis of 5 double-blind, placebo-controlled trials [abstract no. P.2.b.029]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S336.
29. Greenberg W, Gommoll C, Bose A, et al. Levomilnacipran in the treatment of major depressive disorder: an analysis of efficacy and safety data from two phase III studies [abstract no. P.2.c.021]. Eur Neuropsychopharmacol. 2012;22(Suppl 2):S262.
30. Freeman M, Fava M, Gommoll C et al. The efficacy of levomilnacipran ER in the treatment of patients with depression-associated fatigue symptoms [poster no. NR6-100]. Presented at the 167th Annual American Psychiatric Association Meeting; May 3-7 2014, New York.
31. Shiovitz T, Greenberg WM, Chen C, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120 mg/day for prevention of relapse in patients with major depressive disorder. Innov Clin Neurosci. 2014;11(1-2):10-22.
32. Blum SI, Tourkodimitris S, Gommoll C et al. Sustained improvement in functional health and well-being in MDD patients following long-term treatment with levomilnacipran SR [poster]. Presented at the 53rd Annual New Clinical Drug Evaluation Unit Meeting; May 28-31 2013, Hollywood.
33. Mago R, Forero G, Greenberg WM. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013;33(10):761-71.
34. Rutherford BR, Roose SP. A model of placebo response in antidepressant trials. Am J Psychiatry. 2013;170(7):723-33.
35. Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant. What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67(11):1089-104.
36. Fava M, Freeman M, Gommoll C et al. Levomilnacipran ER for fatigue associated with major depressive disorder: a double-blind, randomized, placebo- and active-controlled study [poster]. Presented at the US Psychiatric and Mental Health Congress; Sep 30-Oct 3 2013, Las Vegas.
37. Sambunaris A, Gommoll C, Chen C, et al. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014;29(4):197-205.
38. Blum SI, Tourkodimitris S, Ruth A. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. J Affect Dis. 2014. doi: 10.1016/j.jad.2014.09.005.
39. Palmer R, Shrestha P, Greenberg WM et al. Cardiovascular safety profile of levomilnacipran SR in the treatment of major depressive disorder [poster]. Presented at the 166th Annual American Psychiatric Association Meeting; May 18-22 2013, San Francisco.
40. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16:1433-42.
41. Palmer EC, Binns LN, Carey H. Levomilnacipran: a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Ann Pharmacother. 2014. doi: 10.1177/1060028014535074.